The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLV.a

Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

Publications

Haro-Estarriol M, Sabater-Talaverano G, Rodríguez-Jerez F, Obrador-Lagares A, Genís-Batlle D, Sendra-Salillas S

[Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline].

Archivos de bronconeumologia 2009 Feb;45;100-2 — 2009 Feb — 100-2

Pfitzenmeyer P, Foucher P, Dennewald G, Chevalon B, Debieuvre D, Bensa P, Piard F, Camus P

Pleuropulmonary changes induced by ergoline drugs.

The European respiratory journal 1996 May;9;1013-9 — 1996 May — 1013-9

Dunn JM, Sloan H

Pleural effusion and fibrosis secondary to Sansert administration.

The Annals of thoracic surgery 1973 Mar;15;295-8 — 1973 Mar — 295-8